Exagen Inc.

Exagen is transforming the care continuum for patients affected by chronic autoimmune diseases by enabling timely-differential diagnosis, prognosis, and monitoring while optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products, several of which incorporate their proprietary Cell-Bound Complement Activation Products (CB-CAPs) technology, under the AVISE® brand name. To learn more, visit www.AviseTest.com